Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.10−0.19 (-3.02%)
Close on Nov 18, 2026Market cap $817.84MP/E –Yield –
Immatics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€182.02M. The highest annual figure on record is €29.95M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€182.02M | – |
| FY2024 | Dec 31, 2024 | -€38.62M | – |
| FY2023 | Dec 31, 2023 | -€101.73M | -439.6% |
| FY2022 | Dec 31, 2022 | €29.95M | – |
| FY2021 | Dec 31, 2021 | -€86.29M | – |
| FY2020 | Dec 31, 2020 | -€69.72M | – |
| FY2019 | Dec 31, 2019 | -€33.01M | – |
| FY2018 | Dec 31, 2018 | -€34.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€67.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -€53.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -€26.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -€14.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -€16.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -€23.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -€19.60M | – |
See a number that looks wrong?